New Recruiting Trial: Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
WHY IT MATTERS
This trial offers patients with hematologic malignancies access to a cutting-edge personalized immunotherapy that targets their cancer's unique mutations, potentially offering a new treatment option for those who may have limited alternatives.
Researchers are testing a new cancer treatment that takes a patient's own immune cells, modifies them in a lab to recognize and attack their specific cancer, and then puts them back into the body. This Phase 1 trial is for people with blood cancers like leukemia and lymphoma. The treatment is personalized—each patient's cells are customized based on their individual cancer's unique mutations.
NCT ID: NCT06904066 Title: Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies Status: RECRUITING Phase: PHASE1 Sponsor: National Cancer Institute (NCI) Start date: 2026-04-05 URL: https://clinicaltrials.gov/study/NCT06904066 Source: UniteRare clinical trials database
YOU CAN ACT ON THIS
If you have a hematologic malignancy (blood cancer), check the trial's eligibility requirements at clinicaltrials.gov/study/NCT06904066 and contact the National Cancer Institute to ask if you qualify—enrollment is currently open.